Eisai, GE reach R&D deal for Alzheimer's

04/28/2013 | DOTMed.com · AuntMinnie.com (free registration)

GE Healthcare has announced a collaboration with Eisai focused on research and development of treatments for Alzheimer's disease. GE said its candidate PET agent flutemetamol will be used by Eisai in choosing patients for an early-stage study of Eisai's beta-site amyloid precursor protein-cleaving enzyme inhibitor E2609 as a possible treatment for the disease.

View Full Article in:

DOTMed.com · AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY